Valuation: Strides Pharma Science Limited

Capitalization 9.23TCr 99Cr 84Cr 77Cr 73Cr 136.39Cr 138.86Cr 909.94Cr 356.09Cr 4.43TCr 371.95Cr 364.1Cr 16TCr P/E ratio 2026 *
16.1x
P/E ratio 2027 * 13.8x
Enterprise value 9.23TCr 99Cr 84Cr 77Cr 73Cr 136.39Cr 138.86Cr 909.94Cr 356.09Cr 4.43TCr 371.95Cr 364.1Cr 16TCr EV / Sales 2026 *
1.91x
EV / Sales 2027 * 1.61x
Free-Float
65.68%
Yield 2026 *
0.3%
Yield 2027 * 0.3%
1 day+0.12%
1 week+2.05%
Current month+6.76%
1 month+8.63%
3 months+8.06%
6 months+20.61%
Current year+11.20%
1 week 957
Extreme 957
1,010.9
1 month 870.55
Extreme 870.55
1,010.9
Current year 768.65
Extreme 768.65
1,010.9
1 year 613.2
Extreme 613.2
1,025
3 years 306
Extreme 306
1,675
5 years 263.35
Extreme 263.35
1,675
10 years 263.35
Extreme 263.35
1,675
Manager TitleAgeSince
Chief Executive Officer - 01/06/2024
Director of Finance/CFO 42 01/06/2024
Chief Operating Officer - 01/05/2007
Director TitleAgeSince
Chairman 65 -
Director/Board Member 82 18/05/2017
Director/Board Member 58 11/12/2019
Change 5d. change 1-year change 3-years change Capi.($)
+0.12%+2.05%+62.71%+217.83% 99Cr
-0.16%-2.50%-2.09%+64.64% 4.23TCr
-0.38%-6.57%+55.34%+136.74% 3.46TCr
-1.50%+0.85%-17.22%+32.25% 1.04TCr
-0.30%-6.33%+86.56%+65.43% 1.02TCr
+0.76%+6.48%+6.16%+83.14% 991.22Cr
+1.04%+2.35%+42.14%+115.77% 849.82Cr
-1.14%-15.86%+230.79%+430.61% 822.9Cr
-0.62%-2.19%+52.17%-9.86% 733.09Cr
-0.23%+6.75%+26.66%+67.68% 764.28Cr
Average -0.25%+1.24%+54.32%+120.42% 1.4TCr
Weighted average by Cap. -0.27%-1.12%+39.20%+103.33%

Financials

2026 *2027 *
Net sales 4.83TCr 52Cr 44Cr 40Cr 38Cr 71Cr 73Cr 476.09Cr 186.31Cr 2.32TCr 194.61Cr 190.5Cr 8.24TCr 5.74TCr 62Cr 52Cr 48Cr 45Cr 85Cr 86Cr 565.83Cr 221.43Cr 2.76TCr 231.29Cr 226.41Cr 9.79TCr
Net income 573.7Cr 6.16Cr 5.22Cr 4.81Cr 4.54Cr 8.48Cr 8.63Cr 57Cr 22Cr 275.61Cr 23Cr 23Cr 978.68Cr 668.75Cr 7.18Cr 6.09Cr 5.61Cr 5.29Cr 9.88Cr 10Cr 66Cr 26Cr 321.27Cr 27Cr 26Cr 1.14TCr
Net Debt - -
Logo Strides Pharma Science Limited
Strides Pharma Science Limited is an India-based pharmaceutical company. The Company is focused on the development and manufacture of IP-led niche finished dosage formulations. The Company operates through two segments: Pharmaceutical and Bio-pharmaceutical. Its geographical segment includes Africa, Australia, Asia (excluding India), North America, Europe, India, and Others. The Company manufactures a range of niche and pharmaceutical products, including a range of dosage forms such as liquids, creams and ointments, soft gels, sachets, tablets, and modified release dosage formats. It has eight manufacturing units located in India (Bengaluru-two sites, Puducherry, and Chennai), Singapore, Italy (Milan), the United States (Florida) and Kenya (Nairobi). It is also engaged in manufacturing soft gelatin capsules. It develops and manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drug segments for its institutional business.
Employees
3,301
Date Price Change Volume
13/26/13 1,001.15 +0.11% 2,65,227
10/26/10 1,000.00 +0.38% 2,10,769
09/26/09 996.25 +3.30% 2,64,888
08/26/08 964.40 -2.99% 3,05,152
07/26/07 994.10 +1.33% 1,88,937
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1,001.15INR
Average target price
1,264.00INR
Spread / Average Target
+26.25%

Quarterly revenue - Rate of surprise